Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 26 |
| Active Pipeline (Recruiting Now) | 16 (9) |
| Completed vs Stopped Early | 2 / 1 (3.9%) |
| Median Closed Actual Enrollment | 292 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Henan Cancer Hospital | Zhengzhou, Henan | 5 |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang | 5 |
| Zhejiang Cancer Hospital | Hangzhou, Zhejiang | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06112704 | HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors | Phase II | RECRUITING |
| NCT05830123 | ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas | Phase II | RECRUITING |
| NCT06007729 | ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors | Phase II | RECRUITING |
| NCT06014190 | HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Hansoh BioMedical R&D Company Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.